Aderbasib

N/A

Report date: 2024/06/01 20:00:05
NME

Base Information

Drug NameAderbasib
Drug Alias Name艾德贝塞aderbasibum阿德巴司INC-B007839INCB-007839 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 10 inhibitorsDisintegrin and metalloproteinase domain-containing protein 17 inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17Disintegrin and metalloproteinase domain-containing protein 10
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsOligodendroglioma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesMasonic Cancer Center, University Of MinnesotaIncyte Corp
Active IndicationsOligodendrogliomaDiffuse Intrinsic Pontine GliomaGlioblastoma +[5] 
Inactive IndicationsSolid tumoursBreast NeoplasmsLymphoma, Large B-Cell, Diffuse +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG